TABLE 8.
Single-agent of gastrodin clinical application in neurological disorders.
| Disease | Study type | Gastrodin form, dose and therapy | Control group | Efficacy and results | Adverse events | Refs |
|---|---|---|---|---|---|---|
| IS | Meta-analysis (12 RCTs) | Gastrodin injection | Compound Danshen injection | Total effective rate↑, neural functional deficit score↓ | No obvious adverse reactions | Zhou (2018) |
| Western medicine treatment | The levels of PV, WBV, Hct, RBC AI and FIB↓, the levels of TC, TG, LDL, HDL↓ | |||||
| IS | RCT (n = 106) | Gastrodin injection, 0.6 g (i.v. gtt), once daily for 21 days | Compound Danshen injection | Remission rate (94.3%), GCS scores↑, NIHSS score↓, incidence of adverse reactions↓ | Gastrointestinal symptoms, blood platelet reduce, headache | Xiu-Yun (2020) |
| Migraine | RCT (n = 80) | Gastrodin injection, 0.6 g (i.v.gtt), once daily for 10 days | Flunarizine capsules | Total effective rate (92.5%), VAS score↓, the levels of CGRP, NO and ET↓ | NA | Yang et al. (2017) |
| Post-TBI Syndrome | RCT (n = 90) | Gastrodin sustained-release tablets, 150 mg, twice daily for 4 weeks | Flunarizine capsules | Total effective rate (93.33%), SCL-90 score↓, the levels of IGF-1 and IL-6↓ | No obvious adverse reactions | Xuegong (2015) |
| Gastrodin tablets, 100 mg, three daily for 4 weeks | Total effective rate (73.33%), the levels of IGF-1 and IL-6↓ | |||||
| TBI | RCT (n = 60) | Gastrodin injection, 0.6 g, once daily for 2 weeks | Mouse nerve growth factor injection | Abnormal blood pressure, respiration and heart rate were improved; GCS and MMSE score↑, NIHSS score↓ | Rash | Ming (2015) |
IS, ischemic stroke; RCT, randomized controlled trial; PV, plasma viscosity; WBV, whole blood viscosity; Hct, hematocrit; RBC AI, red blood cell aggregation index; FIB, fibrinogen; TC, total cholesterol; TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density lipoprotein; GCS, glasgow coma scale; NIHSS, national institutes of health stroke scale; VAS, visual analogue scale; CGRP, calcitonin gene-related peptide; NO, nitric oxide; ET, endothelin; NA, not applicable; TBI, traumatic brain injury; SCL-90, Symptom Checklist-90; IGF, insulin-like growth factor; IL, interleukin; MMSE, Mini-Mental State Examination.